Integrating Artificial Intelligence in Drug Discovery
In the last few years, the drug discovery field has seen tremendous advancements in artificial intelligence. Due to its role in RWE analytics and candidate drug identification, artificial intelligence (AI) in drug development is also a contentious area of discussion. Use of AI and ML in drug R&D has been hailed as a new way to cut time, money, and resources. However, the global market for AI in drug development is rising even as experts argue over the technology’s usefulness. As per Transparency Market Research, the global market is projected to cross US$ 10.93 Bn by 2031. If a trend is to be followed, pharma companies must take the lead and proactively adopt the technology.
Although artificial intelligence technology is still in its infancy, it has prompted a paradigm shift in clinical research. Researchers can complete tasks more accurately and quickly by incorporating machine learning (ML), a data-driven branch of AI that automates analytical model development, into clinical processes. This, in turn, allows front-line healthcare personnel to treat patients effectively.
Analytics have long influenced healthcare decision-making.
A priori, mathematical equations were used to describe recurring patterns in data. However, today AI allows scientists to find intricate correlations inside datasets that cannot be seen with traditional, equation-based statistical analysis.
In contrast to human doctors, data-rich computer algorithms with human-like intelligence can see and process enormous amounts of information with pinpoint precision. For instance, analyzing a TB-infected lung, computer vision outperformed the best expert human radiologists in every case, identifying in great detail the sizes of all TB granulomas and the location of any cavities inside each lung. In the future, these algorithms will find correlations where they have not previously been observed, helping researchers make many new discoveries.
Key figures in the healthcare industry are taking notice of the fact that AI has the potential to drastically reduce the financial burden of doing research by improving clinical decision-making and maximizing innovation.
Many organizations are eager to get their hands on AI technology, but it still needs to be put within reach for many smaller companies. Data aggregation, for instance, is still a significant obstacle, and to conform to stringent rules for drug discovery, algorithms also need to be more open and understandable. This essay looks at how much the use of AI speeds up research and sparks new ideas, making it easier to analyze data and find new drugs.
Using AI in Clinical Research
Even though the term “artificial intelligence” isn’t clear, most people understand it to mean machine learning that can do tasks that usually require human intelligence, like seeing, hearing, making decisions, and translating languages. Most AI implementations today are narrow in scope, solving only a few problems.
Artificial intelligence (AI) is typically used in the medical research industry for pattern recognition and data analysis in massive datasets. Significantly faster, more accurate, and more cost-effective than standard analytical procedures, this data can be used to cut costs and boost results.
Similarly, AI may be used to combine disparate datasets and sift through mountains of scientific literature to uncover studies with practical use. According to the World Health Organization, cancer is the second leading cause of death worldwide and accounts for nearly 10 million deaths annually. The AI system will be able to apply machine-learning techniques to identify promising new cancer drugs once it has compiled and “translated” this massive amount of data into a common language. Such advances could make a significant impact on cancer treatments and even reduce cancer mortality rates.
As stated by the U.S. Food and Drug Administration, there are five steps to the usual drug discovery approach.
It all starts with research in the lab. As a next step, the potential candidate undergoes a series of tests before entering clinical trials and testing in humans. The next step is a decision by the FDA on whether or not to approve the medicine. Once a drug or medical device is on the market, the FDA keeps a close eye on it to ensure it is safe for use.
Step 1: Discovery and Development
Research for a new drug begins in the laboratory.
Step 2: Preclinical Research
Drugs undergo laboratory and animal testing to answer basic questions about safety.
Step 3: Clinical Research
Drugs are tested on people to make sure they are safe and effective.
Step 4: FDA Review
FDA review teams thoroughly examine all of the submitted data related to the drug or device and make a decision to approve or not to approve it.
Step 5: FDA Post-Market Safety Monitoring
FDA monitors all drug and device safety once products are available for use by the public.
AI can be used in the first three phases of drug development by companies that use it to speed up and cut costs of research and discovery.
This article summarizes the most significant applications of AI across the drug development life cycle.
Possible Drug Discovery Process:
The preliminary phases of a drug discovery project are crucial. Possible applicants are screened at this point. In the early stages of drug discovery, high throughput screening (HTS) is the most common screening method. Rapid testing of large libraries of compounds is made possible by integrating robotics and automation.
How scientists find a chemical that helps patients:
- By gathering fresh information regarding disease mechanisms
- Molecular testing
- Investigating the unintended consequences of current therapies
- Using advanced methods of technology to handle genetic engineering
It’s at this point that AI can help out. Scientists may use artificial intelligence to sift through the millions of compounds in their databases far more quickly, efficiently, and accurately than is possible with human scientists alone.
Because of this, a less synthetic effort is required to identify molecules with medicinal potential.
The trial’s overall success depends on recruiting the correct patient population. It is the research team’s responsibility to select participants with the highest probability of benefiting from the treatment being examined. Modern healthcare IT uses artificial intelligence to help find patients and locations for trials.
Mainly, researchers use AI and ML algorithms to identify venues with the most extensive recruitment pool and to propose recruitment techniques. The entire selection procedure is bolstered by artificial intelligence and data analytics, from demographic mapping to patient potential prediction.
Patients are matched with trials with the help of automated technologies that assess medical records and real-world evidence.
Approximately 30% to 40% of participants will withdraw from a study at some point. Contrarily, after five months, 40% of patients are still non-adherent, which results in extra expenses for the pharmaceutical sector. The burdensome nature of patient reporting contributes to high attrition rates. Day-to-day data collection includes recording medication taken, body functioning, and other responses.
Regardless, developments in AI are assisting in enhancing patient retention and medicine compliance. When devices like smartwatches, sensors, fitness trackers or monitors and algorithms are used together, patient data can be automatically read and interpreted.
Clinical trial researchers can then receive immediate results from these deep learning models’ data analyses. Dropout risk prediction is another area where predictive analytics vendors can produce insightful models.
The field of RWE analytics examines the usefulness of drugs and medical procedures in actual clinical settings. The pharmaceutical business places a premium on this phenomenon because of its unrealized potential.
This vast trove of information in the medical field serves as a data blanket that can be used for a wide range of analytical purposes. New research paradigms for precision medicine can also be gained using RWE analytics.
Large data sets, including patient outcomes, collected through insurance claims, electronic health records, and other sources are essential for RWE’s cutting-edge analytics.
This information is then utilized to weigh the social benefits of medicine alongside its therapeutic benefits. Data analytics based on real-world evidence is widely recognized as an instrumental component of the drug development process, contributing to the safety and efficacy of treatments while keeping costs down.
Understanding the peculiarities of various patient populations is also a key takeaway from real-world evidence strategy and analytics.
However, tons of computational resources are needed to convert raw data into knowledge to develop real-world evidence. When this occurs, we can rely on artificial intelligence.
Machine learning is a cornerstone of RWE implementation. Intelligent algorithms can be used to generate crucial information to tackle problems that would otherwise take too much time and money to fix.
In particular, machine learning offers novel possibilities for consolidating disparate data sets into a single, authoritative repository. Analytics models can be executed constantly and at scale by tapping into the connected data environments via algorithms.
Trial Data Analysis
Researchers face massive amounts of operational data during study wrap-up. However, the vast majority of insights are hidden by data silos and isolated data architectures. For instance, developing a global trial portfolio takes a lot of work. Dispersed geo-based data is stored in isolated silos on local computers, making it infeasible to put into any analysis rapidly.
Analytics tools with artificial intelligence capabilities can centralize all relevant data and metrics. Algorithms do data cleansing and analysis on trial data and reporting tools display the results graphically to aid decision-making.
The new drug is sent to the FDA for a complete evaluation after undergoing extensive testing and development to ensure its optimal efficacy and safety. The results of clinical trials are reviewed by the FDA, which then decides whether or not to approve the medication.
How can we incorporate real-world data into Drug development process?
RWE’s contributions can be found in every phase of the pharmaceutical industry. Researchers can only explore some feasible therapeutic combo due to a lack of time and money. When paired with automated processing, data analytics applied to evidence from the actual world becomes self-sufficient.
The FDA claims it uses RWE to monitor post-market safety and aid in regulatory decision-making. Healthcare practitioners frequently rely on strategy and analytics based on real-world evidence when making choices about coverage and developing health support tools for use in clinical practice.
Insights from RWE also provide a foundation for clinical trial designs and investigations, which pave the way for novel, data-driven treatment strategies.
Drug development difficulties with artificial intelligence
When compared to more traditional methods, the fact that AI systems can quickly come up with hypotheses for pharmacological targets is a big plus. This makes it possible to look into a broader range of potential treatments and find interesting candidates for more research quickly. But due to several obstacles, AI-developed pharmaceuticals are still in their infancy.
Intelligent systems live upon vast datasets to provide a high accuracy rate. Accordingly, the accessibility and quality of data are two pillars for implementing AI in drug research. Healthcare, however, is one of the sectors that has been hesitant to adopt AI. The main barriers are difficulties gaining access to the data, problems with regulations, and conflicts of interest.
In addition, there needs to be more statistical data because there are so few studies on rare disorders. This hinders scientists’ ability to amass enough information to train an AI algorithm adequately.
Predictive analytics for businesses often deals with relatively simple data, but analyzing a patient’s genetic makeup provides a significant analytical hurdle. There is a complex interaction between a patient’s biological traits and treatment history. Because of this, reactions to medications are often unpredictable. Analysis and prediction of the outcome are both challenging.
So, ML models can accurately predict the effects of combining medications at the dose level. However, determining the impact of more than two medications used together remains challenging. Because of this, there is still a need to change how ML algorithms are used in the pharmaceutical industry.
Disclosure of algorithms
As the most powerful technology, deep learning is the mysterious engine behind AI. Deep learning predictions are spot on, but they are difficult for a human expert to decipher. The fact that it is not deterministic means that it can be processed in various ways. Instead, the result can be seen by researchers without any additional context being provided.
Many organization developers stress the need for smart systems adhering to the four pillars of trust. As their primary goals, all algorithms should be built with fairness, explainability, robustness, and transparency.
For scientists to rely on algorithms for making essential conclusions, the computer’s reasoning must be concealed.
Data privacy and availability
On the route to a unified data analytics pool, the availability of patient datasets is another obstacle. Even though they gather it, hospitals and clinics do not own patients’ personal information. Instead, they are tasked with working as data trustees who are bound to confidentiality.
In this case, the patient owns all of the information. Only with patient permission may data be shared. As a result, most data sets are confidential and cannot be shared for study.
Making new pharmaceuticals is a lengthy and intricate procedure. From the time a drug is first thought of until it receives FDA approval and then hits the market, it is a lengthy process that typically takes around ten years.
However, with AI’s help, we may cut this time in half while reducing drug discovery expenses and increasing precision.
On the other hand, researchers can avoid making medications with hazardous or off-target effects by using AI technology to forecast how molecules will interact.
Problems still exist, but AI-created pharmaceuticals are making their way onto the market. As more and more information becomes available, we should expect to see AI’s latent capabilities fully realized shortly. However, AI is already changing the pharmaceutical industry, so it makes sense to predict that we will begin seeing AI-created drugs in our lifetime.
Leave a Comment
Real-World Evidence and Digital Transformation in Focus: Q&A with Dr. Kavita Lamror
In our latest Real World Evidence Solutions blog, we are privileged to converse with Dr. […]Read More
From Inside Out: How Strategic Talent Mapping Drives Diversity and Equity in Clinical Trials
In the constantly transforming field of Clinical Research and Development, the immense value of diversity […]Read More